Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Geron Corporation (NasdaqNM:GERN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 14Earnings Announcement
Aug 13Conference call: Geron Discusses Development for the Treatment of Cancer
Location
230 Constitution Drive
Menlo Park, CA 94025
Phone: (650) 473-7700
Fax: (650) 473-7701
Email: info@geron.com
Employees (last reported count): 112
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 23%
·Institutional: 15% (20% of float)
(103 institutions)
·Net Inst. Buying: 150.0K shares (+4.37%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Geron Corporation is a biopharmaceutical company focused on discovering, developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron's product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. By activating telomerase, the Company seeks to increase the lifespan of normal cells, which have prematurely aged in the body to treat chronic degenerative diseases. Conversely, by inhibiting telomerase the Company hopes to kill cancer cells where telomerase is abnormally turned on and to diagnose cancer by measuring telomerase activity. Human embryonic stem cells can develop and differentiate into all cells and tissues in the body. Nuclear transfer is a method for generating human cells or whole animals from genetic material derived solely from the nucleus of a single cell obtained from a single individual.
More from Market Guide: Expanded Business Description

Financial Summary
Geron Corporation is engaged in the discovery and development of therapeutic and diagnostic products used to treat cancer and age-related degenerative diseases. For the six months ended 6/30/01, revenues decreased 22% to $2.4 million. Net loss decreased 46% to $13.5 million. Revenues reflect a decrease collaborative agreements due the regaining of rights from Pharmacia. Lower loss reflects lower interest expenses related to convertible debentures.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Alexander Barkas, Ph.D., 53
Chairman
--  --  
Thomas Okarma, Ph.D., M.D., 55
Pres, CEO, Director
$395K--  
David Greenwood, 49
CFO, Sr. VP - Corp. Devel., Sec., Treasurer
280K$1.1M
William Stempel, 47
VP, Gen. Counsel
--  --  
Jeannine Niacaris, 48
VP, HR and Admin. Services
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GERNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$9.125
Recent Price$16.01 
52-Week High
on 5-Sep-2000
$34.188
Beta0.52 
Daily Volume (3-month avg)349.5K
Daily Volume (10-day avg)710.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-52.2%
52-Week Change
relative to S&P500
-35.9%
Share-Related Items
Market Capitalization$350.0M
Shares Outstanding21.9M
Float16.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.45 
Earnings (ttm)-$0.97 
Earnings (mrq)-$0.28 
Sales (ttm)$0.27 
Cash (mrq)$3.44 
Valuation Ratios
Price/Book (mrq)6.54 
Price/EarningsN/A 
Price/Sales (ttm)58.52 
Income Statements
Sales (ttm)$5.94M
EBITDA (ttm)-$22.3M
Income available to common (ttm)-$21.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-18.86%
Return on Equity (ttm)-34.55%
Financial Strength
Current Ratio (mrq)8.01 
Debt/Equity (mrq)0.84 
Total Cash (mrq)$75.2M
Short Interest
As of 8-Aug-2001
Shares Short2.86M
Percent of Float17.0%
Shares Short
(Prior Month)
2.80M
Short Ratio7.25 
Daily Volume395.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.